

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

CD183 (CXCR3)-PE

RRID:AB_2655734

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-101-379, RRID:AB_2655734

Antibody Information

URL: http://antibodyregistry.org/AB_2655734

Proper Citation: Miltenyi Biotec Cat# 130-101-379, RRID:AB_2655734

Target Antigen: CD183 (CXCR3)

Clonality: monoclonal

Comments: Discontinued: 5-2019; Target Distribution T cells, epithelial cells, NK cells, mast cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Antibody Name: CD183 (CXCR3)-PE

Description: This monoclonal targets CD183 (CXCR3)

Target Organism: human

Clone ID: REA232

Antibody ID: AB_2655734

Vendor: Miltenyi Biotec

Catalog Number: 130-101-379

Record Creation Time: 20231110T034431+0000

Record Last Update: 20260901T013319+0000

Ratings and Alerts

No rating or validation information has been found for CD183 (CXCR3)-PE.

Warning: Discontinued: 2021

Discontinued: 5-2019; Target Distribution T cells, epithelial cells, NK cells, mast cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Wendisch D, et al. (2021) SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell, 184(26), 6243.